General University Hospital of Patras
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Andreou, Prematie
NCT03653832: Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial)

Completed
3
1437
Europe
Dexmedetomidine, Dexdor, Clonidine, Catapres, Propofol, Diprivan
University of Edinburgh, West Hertfordshire Hospitals NHS Trust, Queen's University, Belfast, The University of Queensland, University Hospital of Wales, Edinburgh Napier University, King's College London, University of Warwick, University of Manchester, Royal Surrey County Hospital NHS Foundation Trust, University College, London, NHS Lothian, Imperial College London, University of Cambridge
Critical Illness
12/23
07/24
HIBISCUS, NCT04624659: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease

Recruiting
2/3
344
Europe, Canada, US, RoW
Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets
Forma Therapeutics, Inc., Novo Nordisk A/S
Sickle Cell Disease
03/26
04/27
Zafeiropoulou, Vasiliki
HIBISCUS, NCT04624659: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease

Recruiting
2/3
344
Europe, Canada, US, RoW
Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets
Forma Therapeutics, Inc., Novo Nordisk A/S
Sickle Cell Disease
03/26
04/27
Kapota, Athanasia
HIBISCUS, NCT04624659: A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease

Recruiting
2/3
344
Europe, Canada, US, RoW
Etavopivat Tablets Low dose, FT-4202, Etavopivat Tablets High dose, Placebo Tablets, placebo, Etavopivat Tablets
Forma Therapeutics, Inc., Novo Nordisk A/S
Sickle Cell Disease
03/26
04/27

Download Options